Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa

Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a hospital-acquired pathogen with a high mortality rate and limited treatment options. We investigated the activity of ceftolozane/tazobactam (C/T) and its synergistic effects with amikacin to extend the range of optimal therapeutic choices with...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasomsong, Worapong, Nulsopapon, Parnrada, Changpradub, Dhitiwat, Pungcharoenkijkul, Supanun, Hanyanunt, Patomroek, Chatreewattanakul, Tassanawan, Santimaleeworagun, Wichai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026743/
https://www.ncbi.nlm.nih.gov/pubmed/35453269
http://dx.doi.org/10.3390/antibiotics11040517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026743/
https://www.ncbi.nlm.nih.gov/pubmed/35453269
http://dx.doi.org/10.3390/antibiotics11040517

Ejemplares similares